Crossmark

A randomized trial of normothermic preservation in liver transplantation

Crossref DOI link: https://doi.org/10.1038/s41586-018-0047-9

Published Online: 2018-04-18

Published Print: 2018-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

,

Nasralla, David

Coussios, Constantin C.

Mergental, Hynek

Akhtar, M. Zeeshan

Butler, Andrew J.

Ceresa, Carlo D. L.

Chiocchia, Virginia

Dutton, Susan J.

García-Valdecasas, Juan Carlos

Heaton, Nigel

Imber, Charles

Jassem, Wayel

Jochmans, Ina

Karani, John

Knight, Simon R.

Kocabayoglu, Peri

Malagò, Massimo

Mirza, Darius

Morris, Peter J.

Pallan, Arvind

Paul, Andreas

Pavel, Mihai

Perera, M. Thamara P. R.

Pirenne, Jacques

Ravikumar, Reena

Russell, Leslie

Upponi, Sara

Watson, Chris J. E.

Weissenbacher, Annemarie

Ploeg, Rutger J.

Friend, Peter J.
License Information

Text and Data Mining valid from 2018-04-18
More Information

Article History

Received: 28 September 2017

Accepted: 8 March 2018

First Online: 18 April 2018

Change Date: 23 April 2018

Change Type: Update

Change Details: The Source Data files originally published with this article were missing for Extended Data Figures 3 and 4. This has now been corrected.

Competing interests

: P.J.F. is a co-founder, chief medical officer and consultant to OrganOx Limited and also holds shares in the company. C.C.C. is a co-founder, chief technical officer and consultant to OrganOx Limited and also holds shares in the company. Neither P.J.F. nor C.C.C. were involved in the selection, recruitment or transplantation of patients in this study.